Despite these limitations, our study demonstrates, to our knowledge for the first time, the feasibility of stem cell mobilization with the combination of ixazomib and G-CSF in patients with MM and provides promising efficacy data. This evidence concerns the gene CSF3 and Miyoshi myopathy.